IRIS International Announces Third Quarter 2011 Revenue and Financial Results
03 nov. 2011 16h05 HE
|
IRIS International, Inc.
Record revenue of $28.1 million; 9% growth over Q3 2010
Gross margin of 50% in Q3 2011; Excluding Arista, gross margin of 52%
Restructured Personalized Medicine Division by downsizing...
IRIS International to Host Investor Breakfast December 2nd, 2011 In New York
31 oct. 2011 09h00 HE
|
IRIS International, Inc.
CHATSWORTH, Calif., Oct. 31, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables, and a developer of...
IRIS International Receives CE Mark for Its NADiA ProsVue(TM) Prognostic Cancer Test
26 oct. 2011 18h43 HE
|
IRIS International, Inc.
CHATSWORTH, Calif., Oct. 26, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables, and a developer of...
IRIS to Release Third Quarter Financial Results and Host Conference Call and Webcast on Thursday, November 3, 2011
17 oct. 2011 16h10 HE
|
IRIS International, Inc.
CHATSWORTH, Calif., Oct. 17, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables, and a developer of...
IRIS International Reports Granting of Inducement Awards
14 oct. 2011 16h15 HE
|
IRIS International, Inc.
CHATSWORTH, Calif., Oct. 14, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and...
IRIS International Receives FDA 510(k) Clearance for Its NADiA ProsVue(TM) Prognostic Cancer Test
22 sept. 2011 13h48 HE
|
IRIS International, Inc.
CHATSWORTH, Calif., Sept. 22, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables, and a developer of...
IRIS International Announces Restructuring of Personalized Medicine Division
07 sept. 2011 16h05 HE
|
IRIS International, Inc.
Discontinuing non-proprietary testing services – flow cytometry, FISH, cytology services and molecular pathology menu
Retaining CLIA license and commercial capabilities for the...
IRIS International Announces Second Quarter 2011 Revenue and Financial Results
03 août 2011 16h01 HE
|
IRIS International, Inc.
Record Revenue of $30.2 Million; 13% Growth Over Q2 2010
Gross Margin of 52% in Q2 2011
Net Loss of $0.3 Million or Diluted ($0.02) Per Share, Which Includes Arista Net...
IRIS to Release Second Quarter Financial Results and Host Conference Call and Webcast on Wednesday, August 3, 2011
26 juil. 2011 07h00 HE
|
IRIS International, Inc.
CHATSWORTH, Calif., July 26, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), will release its 2011 second quarter financial results after the close of trading on Wednesday, August 3,...
IRIS Introduces the iRICELL(R)1500 Workcell for the U.S. Market at AACC 2011 Annual Meeting and Clinical Lab Expo
25 juil. 2011 07h00 HE
|
IRIS International, Inc.
ATLANTA, July 25, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables, and a provider of high value...